Clinolipid + Intralipid
ApprovedTerminated 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Essential Fatty Acid Deficiency (EFAD)
Conditions
Essential Fatty Acid Deficiency (EFAD)
Trial Timeline
May 1, 2015 โ Oct 1, 2016
NCT ID
NCT02476994About Clinolipid + Intralipid
Clinolipid + Intralipid is a approved stage product being developed by Baxter for Essential Fatty Acid Deficiency (EFAD). The current trial status is terminated. This product is registered under clinical trial identifier NCT02476994. Target conditions include Essential Fatty Acid Deficiency (EFAD).
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04555044 | Approved | Completed |
| NCT02476994 | Approved | Terminated |
Competing Products
20 competing products in Essential Fatty Acid Deficiency (EFAD)